Drug News

First Patient Enrolled in Rise Therapeutics’ Rheumatoid Arthritis Clinical Trial

In a groundbreaking development, Rise Therapeutics, a pioneering clinical-stage biotechnology company, has enrolled its first patient in the Phase 1 clinical trial for R-2487, a synthetic biology-based immunotherapy designed to revolutionize the treatment of rheumatoid arthritis. This crucial milestone marks a significant leap forward not only for Rise Therapeutics but also for the vast population grappling with the challenges of this chronic, systemic inflammatory disorder.

Gary Fanger, the visionary President and Chief Executive Officer of Rise Therapeutics, emphasized the importance of this achievement, stating, “This is an important milestone for the company and patients suffering from rheumatoid arthritis.” Fanger expressed confidence in the company’s commitment to delivering innovative medicines to the clinical community, offering hope to those affected by the debilitating impact of rheumatoid arthritis.

Rheumatoid arthritis affects up to 0.24% of the global population, with as much as 1% of the US population grappling with its effects. The Phase 1 clinical trial (NCT05961592) for R-2487 represents a groundbreaking initiative to understand the safety, pharmacodynamics, and clinical activity of the immunotherapy in patients suffering from rheumatoid arthritis. Conducted at multiple sites across the United States, the trial aims to enroll up to 36 participants, evaluating clinical activity through improvements in disease severity and utilizing key biomarker and pharmacodynamic assessments.


Joan David-Leonhard

Joan David Leonhard is a recent Pharm.D graduate with a strong passion for the pharmaceutical industry and a particular interest in pharmaceutical media and communication. Her brief internship experience includes roles in pharmacy where she built strong patient-pharmacist relationships and a pharmaceutical media internship where she actively contributed to drug information articles, blog posts, social media engagement, and various media projects.
Back to top button

Adblock Detected

Please consider supporting us by disabling your ad blocker